"GlobalCare continues to expand its network based on client demands, and Latin America has become one of the most prominent new clinical trials locations. The standard of medical training in Latin America is high and, due to improvements in the countries' regulatory legislation, investigators are knowledgeable in GCP/ICH guidelines. There are also large numbers of drug-naive subjects. Thus, it made sense to extend GlobalCare's services to this region, cost-effectively delivering high quality and flexible clinical trial services to patients in convenient settings like their home or office," said Gail Adinamis, founder and Chief Executive Officer of GlobalCare.
Reduction in subject recruitment time by over 50% and an increase in subject retention rate of over 95% are among the results that have spurred GlobalCare's rapid growth.
"As industry demand increases for accelerated patient enrollment and streamlined study processes on a global basis, we will continue to expand our network to facilitate the timely and successful completion of clinical trials across biopharmaceuticals while providing important return on investment for sponsors," Adinamis continued.
Therapeutic areas that tend to benefit the most from this model include, but are not limited to, oncology, neurology, infectious disease and the central nervous system. GlobalCare's services are also advantageous for the support of orphan drug studies, where patients typically live significant distances from investigative sites. And, GlobalCare employs an extensive screening and qualification process for its network members and maintains a rigorous quality management system to promote standardization globally while complying with all applicable regulations.
"In addition to our teamwork, quality and responsiveness, GlobalCare works with an unwavering commitment to patient care, safety and ethics," states Adinamis.
Leadership and Exper
|SOURCE GlobalCare Clinical Trials, Ltd|
Copyright©2010 PR Newswire.
All rights reserved